Earlier this week, investors following the pharmaceutical industry may have been surprised to hear that Pfizer was interested in acquiring AstraZeneca. However, the billion-dollar buyout news didn't stop there.

Yesterday, shares of Allergan (NYSE: AGN), the company best-known for its key product Botox, popped more than 15% on news that Valeant Pharmaceuticals (NYSE:BHC) is keen on acquiring it. In the following video, analysts Max Macaluso and Michael Douglass discuss this potential deal, and its implications for investors.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.